Duotrava® ophthalmic drops (hereafter referred to as “brand-name drug”), a fixed-dose combination drug used for the treatment of glaucoma, has one commercially available generic equivalent at February, 2021. In the present study, we compared the brand-name drug and its generic equivalent with respect to viscosity, pH, and osmolality. We measured the mass of a single drop, squeezing force for dispensing a single drop, and number of drops per bottle. We also surveyed healthy individuals on product usability. In addition, we utilized a colorimeter to measure differences in bottle nozzle color and assessed nozzle color visibility among healthy individuals. Results showed that physical properties were nearly identical between the brand-name drug and its generic equivalent. However, bottle usability was significantly higher for the generic equivalent than for the brand-name drug. For both preparations, bottles containing a larger number of drops required greater squeezing force. However, subjects preferred bottles that discharged medication at a consistent squeezing force regardless of the number of drops remaining. The nozzle color assessment revealed that nozzles with high color contrast ratios were more visible than conventional white nozzles, and we observed a correlation between the nozzle color selection rate and contrast ratio. These results suggest the need for comprehensively considering patient usability, especially with regard to the design of the dispensing container, when developing ophthalmic drops.
"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410292350996223361","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Akiyama Shigeo"},{"@language":"ja","@value":"秋山 滋男"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Center for Experiential Pharmacy Practice, Tokyo University of Pharmacy and Life Sciences"},{"@language":"ja","@value":"東京薬科大学 薬学部 薬学 実務実習教育センター"}]},{"@id":"https://cir.nii.ac.jp/crid/1410292350996223365","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Doi Nobuyuki"},{"@language":"ja","@value":"土井 信幸"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"高崎健康福祉大学 薬学部 地域医療薬学研究室"},{"@language":"en","@value":"Laboratory of Community Healthcare, Faculty of Pharmacy, Takasaki University of Health and Welfare"}]},{"@id":"https://cir.nii.ac.jp/crid/1410292350996223363","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Tanuma Kazunori"},{"@language":"ja","@value":"田沼 和紀"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"株式会社カメガヤ（フィットケア・デポ）"},{"@language":"en","@value":"Kamegaya Co, Ltd (Fit Care Depot)"}]},{"@id":"https://cir.nii.ac.jp/crid/1410292350996223364","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kawakami Ayano"},{"@language":"ja","@value":"川上 彩乃"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"東京薬科大学 薬学部 薬学 実務実習教育センター"},{"@language":"en","@value":"Center for Experiential Pharmacy Practice, Tokyo University of Pharmacy and Life Sciences"}]},{"@id":"https://cir.nii.ac.jp/crid/1410292350996223362","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Hori Yusuke"},{"@language":"ja","@value":"堀 祐輔"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Center for Experiential Pharmacy Practice, Tokyo University of Pharmacy and Life Sciences"},{"@language":"ja","@value":"東京薬科大学 薬学部 薬学 実務実習教育センター"}]},{"@id":"https://cir.nii.ac.jp/crid/1410292350996223360","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Miyamoto Etsuko"},{"@language":"ja","@value":"宮本 悦子"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"特定非営利活動法人 健康・環境・教育の会 アカンサス薬局"},{"@language":"en","@value":"Acanthus Pharmacy, Non Profit Organization Health & Welfare・Eco-Protect・Area Contribution・Refresh Education・Town Communication"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"1346342X"},{"@type":"LISSN","@value":"1346342X"},{"@type":"EISSN","@value":"18821499"}],"prism:publicationName":[{"@language":"en","@value":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)"},{"@language":"ja","@value":"医療薬学"},{"@language":"en","@value":"Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)"},{"@language":"en","@value":"JJPHCS"},{"@language":"en","@value":"Jpn. J. Pharm. Health Care Sci."},{"@language":"ja","@value":"医療薬学"}],"dc:publisher":[{"@language":"en","@value":"Japanese Society of Pharmaceutical Health Care and Sciences"},{"@language":"ja","@value":"一般社団法人日本医療薬学会"}],"prism:publicationDate":"2021-06-10","prism:volume":"47","prism:number":"6","prism:startingPage":"326","prism:endingPage":"334"},"reviewed":"false","url":[{"@id":"https://www.jstage.jst.go.jp/article/jjphcs/47/6/47_326/_pdf"}],"availableAt":"2021-06-10","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=glaucoma","dc:title":"glaucoma"},{"@id":"https://cir.nii.ac.jp/all?q=combination%20drug","dc:title":"combination drug"},{"@id":"https://cir.nii.ac.jp/all?q=ophthalmic%20drops","dc:title":"ophthalmic drops"},{"@id":"https://cir.nii.ac.jp/all?q=dispensing%20bottle%20nozzle","dc:title":"dispensing bottle nozzle"},{"@id":"https://cir.nii.ac.jp/all?q=visibility","dc:title":"visibility"},{"@id":"https://cir.nii.ac.jp/all?q=usability","dc:title":"usability"},{"@id":"https://cir.nii.ac.jp/all?q=glaucoma","dc:title":"glaucoma"},{"@id":"https://cir.nii.ac.jp/all?q=combination%20drug","dc:title":"combination drug"},{"@id":"https://cir.nii.ac.jp/all?q=ophthalmic%20drops","dc:title":"ophthalmic drops"},{"@id":"https://cir.nii.ac.jp/all?q=dispensing%20bottle%20nozzle","dc:title":"dispensing bottle nozzle"},{"@id":"https://cir.nii.ac.jp/all?q=visibility","dc:title":"visibility"},{"@id":"https://cir.nii.ac.jp/all?q=usability","dc:title":"usability"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360001114030492032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360008373650550528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Persistence with topical glaucoma therapy among newly diagnosed Japanese patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298342532376576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incidence of dyschromatopsy in glaucoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298345305729536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861293034044800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acquired colour vision defects in glaucoma---their detection and clinical significance"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518956474112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Optical and retinal factors affecting visual resolution."}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896067537536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adherence in Glaucoma: Objective Measurements of Once-Daily and Adjunctive Medication Use"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001288152312704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Influences of Eye Drop Containers on the Subjective Usability of a High-viscosity Eye Drop Suspension (AZORGA® Combination Ophthalmic Suspension)"},{"@language":"ja","@value":"点眼容器の違いが高粘度懸濁性点眼液（アゾルガ®配合懸濁性点眼液）の使用感に与える影響"}]},{"@id":"https://cir.nii.ac.jp/crid/1390003825195641344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"連載 今月の話題 今までと異なる組み合わせの緑内障配合点眼薬をマスターしよう"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679478766720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"後発医薬品の使用促進における政府の取組"}]},{"@id":"https://cir.nii.ac.jp/crid/1390301142874715904","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Evaluation of Physical Properties and Usability of Brimonidine Tartrate Ophthalmic Solution for the Treatment of Glaucoma in Brand-name and Generic Drug Formulations"},{"@language":"ja","@value":"ブリモニジン酒石酸塩点眼液の先発医薬品・後発医薬品の物性および使用性に関する製剤評価"}]},{"@id":"https://cir.nii.ac.jp/crid/1390564238102635008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of Brand-Name and Generic Products of Latanoprost Timolol Maleate Ophthalmic Solution with Respect to the Formulation and Usability"},{"@language":"ja","@value":"ラタノプロスト・チモロールマレイン酸塩配合点眼液の先発医薬品と後発医薬品の製剤学的評価および使用性の比較検討"},{"@language":"ja-Kana","@value":"ラタノプロスト ・ チモロールマレイン サンエン ハイゴウ テンガンエキ ノ センパツ イヤクヒン ト コウハツ イヤクヒン ノ セイザイガクテキ ヒョウカ オヨビ シヨウセイ ノ ヒカク ケントウ"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2009398948"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.47.326"},{"@type":"OPENAIRE","@value":"doi_________::ff74aee404f93c9fea4fd029949bbdd6"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.49.310_references_DOI_Uh8ZeRP7joSNf0B7WrMmKq5iWWS"}]}